The company is making its mark through strategic initiatives, promising to become a significant presence in the evolving pharmaceutical sector
First patient enrolled in the Phase III SOHO-02 trial of investigational agent BAY 2927088 in treatment-naïve patients with advanced NSCLC with HER2-activating mutations
New analyses, including presentations on mavacamten, apixaban and milvexian, further solidify the company's strength and expertise as a leader in cardiovascular diseases
GSK and Flagship to jointly fund up to $150 million upfront
Finance Minister Nirmala Sitharaman is set to present the full budget for the current financial year on July 23
Doxorubicin Hydrochloride Liposome Injection (RLD Doxil) had estimated annual sales of USD 42 million in the U.S. (IQVIA MAT May 2024)
Aim of the collaboration is to develop mRNA platform technology, scale up and troubleshoot challenges in mRNA process optimization
Yann d’Hervé takes over responsibility for the Health Care business at Evonik, effective July 1
Offering testing, treatment and support to help stop the spread of HIV and other infectious diseases
DSP-5336, an Investigational Menin and Mixed-lineage Leukemia Inhibitor, is Being Evaluated in Patients with Relapsed or Refractory Acute Leukemia
Subscribe To Our Newsletter & Stay Updated
